Rank Profit for the Year
Rank in industry
3/1,413
"Top 10%"
Rank in Denmark
7,944/303,195
"Top 10%"
Top management Top 3
| Jakob Oemar Gjørret 1 | CEO |
Board Top 3
| Lars Linaa Jørgensen 3 | Chairman of board |
| Pernille Bundgaard 1 | Boardmember |
| Jakob Oemar Gjørret 1 | Boardmember |
Legal owners Top 3
Rights certificate
Selskabet tegnes af den administrerende direktør i forening med bestyrelsens formand eller af den administrerende direktør i forening med to bestyrelsesmedlemmer.
Company information based on CVR
| Name | Unilabs A/S |
|---|---|
| Alternate names | Capio Danmark A/S, Capio Diagnostik A/S, Nova Medical Medi-Lab A/S, Mova Medical F.A. A/S, Nova Medical Danmark A/S, Nova Medical F.A. A/S Show more |
| CVR | 29458219 |
| Address | Nygårdsvej 32, 2100 København Ø |
| Industry | Other human health activities n.e.c. [869090] |
| Web | http:// |
| Established | 17-12-1969 (51 yr) |
| Company type | Limited Corporation |
| Number of employees | 55 (Fin.Stmt) |
| Advertising protection | No |
| Auditor | Pricewaterhousecoopers Statsautoriseret Revisionspartnerselskab since 22-12-2014 |
| Financial statement period | 01-01 to 31-12 |
| Company capital | 2,000,000 DKK |
| Articles of assoc. last | 19-05-2017 |
Member of industries
- Other human health activities n.e.c.NACE6 containing 10,104 comp.
- Other human health activitiesNACE3 containing 21,386 comp.
- Human health activitiesNACE2 containing 31,120 comp.
- Human health and social work activitiesNACE1 containing 43,722 comp.
Purpose
Selskabets formål er a) Udvikling og udførelse af analyser og kliniske laboratorieundersøgelser for hospitaler, specialister og praktiserende læger, forskning samt produktudvikling i lægemiddel- og biotekindustrien og enhver virksomhed i forbindelse hermed. b) Det er desuden selskabets formål at udføre billeddiagnostiske undersøgelser - herunder MR, ultralyd, mammografi og røntgen for samme kundegrupper c) Enhver form for virksomhed, som i videste forstand direkte eller indirekte kan tjene til fremme af de ovennævnte formål.
Financial Statement
| 2019 | 2018 | 2017 | |
|---|---|---|---|
| Currency/unit | 000' DKK | 000' DKK | 000' DKK |
| Revenue | - - | - - | - - |
| Gross Profit | 53,589 +2% | 52,694 -13% | 60,780 -11% |
| Profit for the Year | 12,124 +0% | 12,098 +77% | 6,844 -61% |
| Equity | 96,473 +14% | 84,349 +17% | 72,251 +10% |
| Total Assets | 115,278 +11% | 104,018 -12% | 117,618 +1% |
Mangement review
Væsentligste aktiviteter
Selskabets formål er udvikling og udførelse af klinisk biokemiske analyser til sundhedssektoren samt til medicinal-, biotek- og deviceindustrien såvel nationalt som internationalt.
Tidligere var det også en del af selskabets formål at udføre billeddiagnostiske undersøgelser – med hovedfokus på teleradiologi for samme kundegrupper. Denne service blev lukket ned i 2018
Udvikling i året
Selskabets resultatopgørelse for 2019 udviser et overskud på TDKK 12.124, og selskabets balance pr. 31. december 2019 udviser en egenkapital på TDKK 96.473.
Året der gik og opfølgning på sidste års forventede udvikling
I 2019 steg bruttofortjenesten med 2 %.
Virksomheden er inddelt i 2 segmenter: den danske sundhedssektor og drug development/pharma.
Den danske sundhedssektor, har vist en nedadgående trend de seneste år grundet stigende in sourcing i den offentlige sektor.
Trods en betydelig stigning i projekter for udvikling af lægemidler, blev den forventede stigning dog ikke realiseret.
Målsætninger og forventninger for det kommende år
For 2020 forventes pharma segmentet at stå for den positive udvikling af forretningen. In-sourcing af den danske sygehussektor forventes at fortsætte resten af året.
Udbruddet af Covid-19 i Q1 2020 har påvirket forretningsmiljøet, så vel som voluminerne. Pandemien forventes at medføre en mindre stigning i Pharma segmentet end oprindelig forventet i dette år, så vel som en yderligere nedgang i voluminerne fra den danske sundheds sektor.
Begivenheder efter balancedagen
Covid-19 pandemien udbrød i Europa i slutningen af Q1 2020. Virksomheden har set en negativ påvirkning af sin forretning der er relateret til pandemien i forhold til lavere voluminer, så vel som i forsinkelse af igangværende kliniske projekter og indgåelse af nye projekter. Yderligere beskrivelse fremgår af omtalen af begivenheder efter balancedagen i note 1.
Derudover er der ikke indtruffet hændelser efter regnskabsårets udløb, som har betydning for Unilabs finansielle stilling pr. 31. december 2019, Key activities
The mission of the Company is to develop and carry out clinical biochemistry assays for the health sector as well as for the pharma, biotech and device industries, nationally as well internationally.
Formerly the Company also performed diagnostic imaging examinations – with main focus on teleradiology for the same customer groups. However, such services were terminated during 2018.
Development in the year
The income statement of the Company for 2019 shows a profit of TDKK 12,124, and at 31 December 2019 the balance sheet of the Company shows equity of TDKK 96,473.
The past year and follow-up on development expectations from last year
In 2019 gross margin increased by 2 %.
The business is divided in 2 main segments: the Danish healthcare market and the drug development/pharma market.
The Danish healthcare market has shown a downward trend in recent years due to increased in sourcing in the public sector.
Although significant growth was achieved, the expected increase in new pharma projects was not fully realized during the year.
Targets and expectations for the year ahead
For 2020, the pharma segment is expected to lead the positive development of the business. The insourcing trend in the Danish healthcare market is expected to continue during the year.
The outbreak of Covid-19 in Q1 2020 has impacted the business environment as well as the volumes. The pandemic is expected to lead to less growth in the pharma segment than initially expected in the year as well as a further decline in volumes from the Danish healthcare sector.
Subsequent events
The Covid-19 pandemic broke out in Europe in the later part of Q1 2020. The Company has seen negative impact on its business related to the pandemic in terms of lower volumes as well as delays in ongoing clinical trial projects and contracting of new projects. This is further described in note 1 regarding subsequent events.
Beside the above, no events material to the assessment of the Annual Report have occurred after the balance sheet date.
Selskabets formål er udvikling og udførelse af klinisk biokemiske analyser til sundhedssektoren samt til medicinal-, biotek- og deviceindustrien såvel nationalt som internationalt.
Tidligere var det også en del af selskabets formål at udføre billeddiagnostiske undersøgelser – med hovedfokus på teleradiologi for samme kundegrupper. Denne service blev lukket ned i 2018
Udvikling i året
Selskabets resultatopgørelse for 2019 udviser et overskud på TDKK 12.124, og selskabets balance pr. 31. december 2019 udviser en egenkapital på TDKK 96.473.
Året der gik og opfølgning på sidste års forventede udvikling
I 2019 steg bruttofortjenesten med 2 %.
Virksomheden er inddelt i 2 segmenter: den danske sundhedssektor og drug development/pharma.
Den danske sundhedssektor, har vist en nedadgående trend de seneste år grundet stigende in sourcing i den offentlige sektor.
Trods en betydelig stigning i projekter for udvikling af lægemidler, blev den forventede stigning dog ikke realiseret.
Målsætninger og forventninger for det kommende år
For 2020 forventes pharma segmentet at stå for den positive udvikling af forretningen. In-sourcing af den danske sygehussektor forventes at fortsætte resten af året.
Udbruddet af Covid-19 i Q1 2020 har påvirket forretningsmiljøet, så vel som voluminerne. Pandemien forventes at medføre en mindre stigning i Pharma segmentet end oprindelig forventet i dette år, så vel som en yderligere nedgang i voluminerne fra den danske sundheds sektor.
Begivenheder efter balancedagen
Covid-19 pandemien udbrød i Europa i slutningen af Q1 2020. Virksomheden har set en negativ påvirkning af sin forretning der er relateret til pandemien i forhold til lavere voluminer, så vel som i forsinkelse af igangværende kliniske projekter og indgåelse af nye projekter. Yderligere beskrivelse fremgår af omtalen af begivenheder efter balancedagen i note 1.
Derudover er der ikke indtruffet hændelser efter regnskabsårets udløb, som har betydning for Unilabs finansielle stilling pr. 31. december 2019, Key activities
The mission of the Company is to develop and carry out clinical biochemistry assays for the health sector as well as for the pharma, biotech and device industries, nationally as well internationally.
Formerly the Company also performed diagnostic imaging examinations – with main focus on teleradiology for the same customer groups. However, such services were terminated during 2018.
Development in the year
The income statement of the Company for 2019 shows a profit of TDKK 12,124, and at 31 December 2019 the balance sheet of the Company shows equity of TDKK 96,473.
The past year and follow-up on development expectations from last year
In 2019 gross margin increased by 2 %.
The business is divided in 2 main segments: the Danish healthcare market and the drug development/pharma market.
The Danish healthcare market has shown a downward trend in recent years due to increased in sourcing in the public sector.
Although significant growth was achieved, the expected increase in new pharma projects was not fully realized during the year.
Targets and expectations for the year ahead
For 2020, the pharma segment is expected to lead the positive development of the business. The insourcing trend in the Danish healthcare market is expected to continue during the year.
The outbreak of Covid-19 in Q1 2020 has impacted the business environment as well as the volumes. The pandemic is expected to lead to less growth in the pharma segment than initially expected in the year as well as a further decline in volumes from the Danish healthcare sector.
Subsequent events
The Covid-19 pandemic broke out in Europe in the later part of Q1 2020. The Company has seen negative impact on its business related to the pandemic in terms of lower volumes as well as delays in ongoing clinical trial projects and contracting of new projects. This is further described in note 1 regarding subsequent events.
Beside the above, no events material to the assessment of the Annual Report have occurred after the balance sheet date.
26-05-2020